Alan D. Barrett, Ph.D.

Alan D. Barrett, Ph.D.

Director, Sealy Center for Vaccine Development;
Professor, Department of Pathology;
Professor, Department of Microbiology & Immunology;
Member, Center for Biodefense and Emerging Infectious Diseases;
Member, Institute for Human Infections and Immunity;
Member, Experimental Pathology Graduate Program
Member, Microbiology & Immunology Graduate Program

University of Texas Medical Branch
3.230 Mary Moody Northern Building
301 University Boulevard
Galveston, TX 77555-0436

Office: (409) 772-6662
Fax: (409) 772-6663
abarrett@utmb.edu

« Back

Alan D. Barrett, Ph.D.

Professional Education

Degree Institution Field of Study Graduation Year
B.S. University of Warwick, Coventry, U.K Microbiology & Virology 1978
D.V.M. University of Warwick, Coventry, U.K Virology 1980
Ph.D. University of Warwick, Coventry, U.K Virology 1983
Post-Doctoral Fellow Arbovirus Research Unit, London School of Hygiene and Tropical Medicine, UK    

Honors

2009-Present

John D. Stobo, M.D. Distinguished Chair

2008 Eagleson Lecturer, Annual Meeting of the American Biological Safety Association
2004-2005 UTMB Graduate School of Biomedical Sciences Dr Leon Bromberg Professor for Excellence in Teaching
2003-2005 American Society for Microbiology-Waksman Foundation for Microbiology lecturer

Professional Affiliations

  • 2010-2013 Associate Editor, Vaccine
  • 2005-2009 Editor, Journal of General Virology
  • Member, Editorial Boards of Virus Research, Journal of Virological Methods, Journal of Virology, Journal of General Virology, Journal of Medical Virology and Pan Amazonian Health Journal
  • Member, American Society for Virology, American Society for Microbiology, International Society for Vaccines and Society for General Microbiology

Research Interests

Our laboratory is undertaking basic research on the development of vaccines against the flavivirus diseases. This includes West Nile, Japanese encephalitis, yellow fever and dengue. We undertake studies on the excellent yellow fever 17D vaccine as a model to understand the molecular basis of attenuation of this vaccine. This is of major importance as the 17D vaccine virus is being used as an attenuated backbone to generate chimeric vaccine viruses against other flavivirus diseases, including dengue and Japanese encephalitis. In addition, recombinant DNA technology and infectious clone technology/reverse genetics are being used to identify molecular determinants of virulence of yellow fever, West Nile and Japanese encephalitis viruses with the aim of mutating these virulence determinants to develop candidate attenuated vaccine strains. We also investigate the moelcular epidmeiology of various flaviviruses (yellow fever, West Nile, Japanese encephalitis, and St Louis encephalitis viruses).

Selected Publications

  1. Volk DE, Gandham SHA, May FJ, Anderson A, BARRETT ADT and Gorenstein DG NMR Assignments of the Yellow Fever Virus Envelope Protein Domain III.Biomolecular NMR Assignments 1:49-50, 2007. PMID: 19636823
  2. Volk DE, Lee YC,Li X, Thiviyanathan V, Gromowski GD, Li L, Lamb AR, Beasley DW, BARRETT AD and Gorenstein DG. Solution structure of the envelope protein domain III of dengue-4 virus. Virology 364:147-54, 2007. doi:10.1016/j.virol.2007.02.023
  3. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, BARRETT AD, Fremont DH, and Diamond MS. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognized adjacent epitopes. J Virol 81:12816-26, 2007. http://jvi.asm.org/cgi/content/full/81/23/12816?view=long&pmid=17881453
  4. Ferguson M, Jones S, Li L, Heath A, and BARRETT ADT. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines- report of a collaborative study on PRNT50 assays for Japanese encephalitis (JE) antibodies. Biologicals 36: 111-6, 2008. doi:10.1016/j.biologicals.2007.07.002
  5. Maillard RA, Jordan M, Beasley DWC, BARRETT ADT and Lee JC. Long Range Communication in the Envelope Protein Domain III and Its Effect on the Resistance of West Nile Virus to Antibody-mediated Neutralization. J Biol Chem. 283:613-22, 2008. doi:10.1074/jbc.M706031200
  6. May FJ, Li L, Zhang S, Guzman H, Beasley DWC, Tesh RB, Higgs S, Raj P, Bueno R, Randle Y, Chandler L, BARRETT ADT. Genetic variation of St Louis encephalitis virus. J. Gen Virol 89: 1901-1910. http://vir.sgmjournals.org/cgi/content/full/89/8/1901
  7. Gromowski GD, Barrett ND and BARRETT ADT. Characterization of dengue complex-specific neutralizing epitopes on the envelope protein domain III of dengue 2 virus. J Virol. 82: 8828-8837, 2008. http://jvi.asm.org/cgi/content/full/82/17/8828?view=long&pmid=18562544
  8. Vanlandingham D, McGee C, Klingler K, Galbraith S, BARRETT ADT and Higgs S. Comparison of oral infectious dose of West Nile virus isolates representing three different genotypes in Culex quinquefasciatus. Am J Trop Med Hyg 79: 951-954, 2008. PMID: 19052310
  9. Volk DE, Anderson KM, Gandham SH, May FJ, Li L, Beasley DW, BARRETT AD, Gorenstein DG. NMR assignments of the sylvatic dengue 1 virus envelope protein domain III. Biomol NMR Assign. 2008 Dec;2(2):155-7, 2008. PMID: 19636893
  10. Matsui K, Gromowski GD, Li L, Schuh AJ, Lee JC and BARRETT ADT. Characterization of Dengue Complex-specific Epitopes on Dengue 3 Virus Envelope Protein Domain III. Virology (Rapid Communication) 384:16-20, 2009. PMID: 19201005
  11. Volk DE, May FJ, Gandham SH, Anderson A, Von Lindern JJ, Beasley DW, BARRETT AD, Gorenstein DG. Structure of yellow fever virus envelope protein domain III. Virology 394(1):12-8, 2009. PMID: 19818466
  12. Schuh AJ, Li L, Innis BL and BARRETT, ADT. Genetic characterization of early isolates of Japanese encephalitis virus: Genotype II has been circulating since at least 1951. J Gen Virol, 91:95-102, 2010. PMID: 19776238
  13. Zhang S, Bovshik EI, Maillard R, Gromowski GD, Volk DE, Schein CH, Huang CYH, Gorenstein DG, Lee JC, BARRETT ADT and Beasley DWC. Role of BC loop residues in structure, function and antigenicity of the West Nile virus envelope protein receptor binding domain III. Virology, Virology 403: 85-91, 2010. PMID: 20447672
  14. May FJ, Li L, Davis CT, Galbraith SE and BARRETT ADT. Multiple Pathways to the Attenuation of West Nile virus in South East Texas in 2003. Virology 405: 8-14, 2010. PMID: 20580395
  15. Whiteman MC, Li L, Wicker, HA, Kinney RM, Huang C, Beasley DWC, Chung KM, Diamond MS, Solomon T and BARRETT ADT. Development and characterization of nonglycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine 28:1075-83, 2010. PMID: 19896447
  16. Laurent-Rolle M, Boer EF, Lubick KJ, Wolfinbarger JB, Carmody AB, Rockx B, Liu W, Ashour J, Shupert WL, Holbrook MR, BARRETT ADT, Mason PW, Bloom ME, Garcia­-Sastre A, Khromykh AA, Best SM. The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol 84: 3503-15. 2010 PMID: 20106931
  17. Auguste AJ, Lemey P, Pybus OG, Suchard MA, Salas RA, Adesiyun AA, Barrett AD, Tesh RB, Weaver SC, Carrington CV.2010. Yellow fever virus maintenance in Trinidad and its dispersal throughout the Americas. J Virol. 84:9967-77, 2010. PMID: 20631128
  18. Gromowski GD, Roehrig JT, Diamond MS, Lee JC, Pitcher, TJ and BARRETT ADT. Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. Virology 407: 237-46, 2010. PMID: 20832836
  19. Matsui K, Gromowski GD, Li L and BARRETT ADT. Characterization of a Dengue Type-Specific Epitope on Dengue 3 Virus Envelope Protein Domain III. J Gen Virol 91: 2249-2253, 2010 PMID: 20444995
  20. Schuh AJ, Tesh R, BARRETT ADT. Genetic characterization of Japanese encephalitis virus genotype II strains isolated from 1951 to 1978. J Gen Virol 92: 516 – 527, 2011 PMID: 21123550

NIH Biosketch